Clinical evaluations involving Eledon's asset tegoprubart in investigator-initiated islet cell transplantation trials have yielded highly encouraging results for type 1 diabetes patients. Updated data presented at major medical meetings demonstrated that patients achieved complete insulin independence following transplants supported by tegoprubart-based immunosuppression. These findings highlight its potential to protect transplanted insulin-producing cells from immune destruction without typical nephrotoxic side effects.